Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
154.47
+0.42 (0.27%)
At close: Apr 13, 2026, 4:00 PM EDT
154.47
0.00 (0.00%)
After-hours: Apr 13, 2026, 4:00 PM EDT
Novartis AG Employees
Novartis AG had 75,267 employees as of December 31, 2025. The number of employees decreased by 616 or -0.81% compared to the previous year.
Employees
75,267
Change (1Y)
-616
Growth (1Y)
-0.81%
Revenue / Employee
$752,973
Profits / Employee
$185,792
Market Cap
294.69B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75,267 | -616 | -0.81% |
| Dec 31, 2024 | 75,883 | -174 | -0.23% |
| Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
| Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
| Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
| Dec 31, 2020 | 105,794 | 1,880 | 1.81% |
| Dec 31, 2019 | 103,914 | -21,247 | -16.98% |
| Dec 31, 2018 | 125,161 | 3,564 | 2.93% |
| Dec 31, 2017 | 121,597 | 3,204 | 2.71% |
| Dec 31, 2016 | 118,393 | -307 | -0.26% |
| Dec 31, 2015 | 118,700 | -14,713 | -11.03% |
| Dec 31, 2014 | 133,413 | -2,283 | -1.68% |
| Dec 31, 2013 | 135,696 | 7,972 | 6.24% |
| Dec 31, 2012 | 127,724 | 4,038 | 3.26% |
| Dec 31, 2011 | 123,686 | 4,268 | 3.57% |
| Dec 31, 2010 | 119,418 | 19,584 | 19.62% |
| Dec 31, 2009 | 99,834 | 3,117 | 3.22% |
| Dec 31, 2008 | 96,717 | -1,483 | -1.51% |
| Dec 31, 2007 | 98,200 | -2,535 | -2.52% |
| Dec 31, 2006 | 100,735 | 9,735 | 10.70% |
| Dec 31, 2005 | 91,000 | 9,600 | 11.79% |
| Dec 31, 2004 | 81,400 | 2,859 | 3.64% |
| Dec 31, 2003 | 78,541 | 5,664 | 7.77% |
| Dec 31, 2002 | 72,877 | 2,557 | 3.64% |
| Dec 31, 2001 | 70,320 | 1,252 | 1.81% |
| Dec 31, 2000 | 69,068 | -13,391 | -16.24% |
| Dec 31, 1999 | 82,459 | -3,376 | -3.93% |
| Dec 31, 1998 | 85,835 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Merck & Co. | 75,000 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
NVS News
- 4 days ago - Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030 - GlobeNewsWire
- 15 days ago - Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3% - GlobeNewsWire
- 17 days ago - Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week - CNBC
- 17 days ago - Novartis to Buy Biotech Excellergy for Up to $2 Billion - WSJ
- 17 days ago - Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion - Reuters
- 17 days ago - Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors - GlobeNewsWire
- 17 days ago - Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation - GlobeNewsWire
- 21 days ago - Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026 - GlobeNewsWire